Solid Tumor Biology Program,
James Comprehensive Cancer Center,
Department of Neurological Surgery,
Solid Tumor Biology Program, James Comprehensive Cancer Center,
Department of Neurological Surgery, James Comprehensive Cancer Center
Balveen Kaur has not added Biography.
If you are Balveen Kaur and would like to personalize this page please email our Author Liaison for assistance.
Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation.
Advances in anatomic pathology Jan, 2002 | Pubmed ID: 11756757
Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells.
Cancer research May, 2002 | Pubmed ID: 11980636
Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
Cancer research May, 2002 | Pubmed ID: 12019170
Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.
Frontiers in bioscience : a journal and virtual library Jan, 2003 | Pubmed ID: 12456339
Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression.
The American journal of pathology Jan, 2003 | Pubmed ID: 12507886
Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population.
Cancer research Feb, 2004 | Pubmed ID: 14871821
Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research Dec, 2004 | Pubmed ID: 15623644
Genetic and hypoxic regulation of angiogenesis in gliomas.
Journal of neuro-oncology Nov, 2004 | Pubmed ID: 15674480
Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor.
Oncogene May, 2005 | Pubmed ID: 15782143
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.
Neuro-oncology Apr, 2005 | Pubmed ID: 15831232
Gene therapeutics: the future of brain tumor therapy?
Expert review of anticancer therapy Jul, 2006 | Pubmed ID: 16831077
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
Proceedings of the National Academy of Sciences of the United States of America Aug, 2006 | Pubmed ID: 16908838
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging.
Molecular therapy : the journal of the American Society of Gene Therapy Dec, 2006 | Pubmed ID: 16996314
Personalizing oncolytic virotherapy?
Molecular therapy : the journal of the American Society of Gene Therapy Jan, 2007 | Pubmed ID: 17164767
Oncolytic viruses driven by tumor-specific promoters.
Current cancer drug targets Mar, 2007 | Pubmed ID: 17346110
Oncolytic viruses: extreme treatment for an extreme disease.
Future microbiology Dec, 2006 | Pubmed ID: 17661625
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses.
Cancer research Oct, 2007 | Pubmed ID: 17909049
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy.
Journal of the National Cancer Institute Dec, 2007 | Pubmed ID: 18042934
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61.
Molecular therapy : the journal of the American Society of Gene Therapy Aug, 2008 | Pubmed ID: 18545226
Advances in oncolytic virus therapy for glioma.
Recent patents on CNS drug discovery Jan, 2009 | Pubmed ID: 19149710
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism.
Cancer research Feb, 2009 | Pubmed ID: 19176395
Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas.
Journal of neuro-oncology Sep, 2009 | Pubmed ID: 19381449
Pharmacologic and chemical adjuvants in tumor virotherapy.
Chemical reviews Jul, 2009 | Pubmed ID: 19462957
Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1.
Molecular therapy : the journal of the American Society of Gene Therapy Feb, 2010 | Pubmed ID: 19844198
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.
Current gene therapy Oct, 2009 | Pubmed ID: 19860649
Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin.
The American journal of pathology Apr, 2010 | Pubmed ID: 20167858
Directing systemic oncolytic viral delivery to tumors via carrier cells.
Cytokine & growth factor reviews Apr-Jun, 2010 | Pubmed ID: 20226717
Impact of tumor microenvironment on oncolytic viral therapy.
Cytokine & growth factor reviews Apr-Jun, 2010 | Pubmed ID: 20399700
Chondroitinase ABC I-mediated enhancement of oncolytic virus spread and antitumor efficacy.
Clinical cancer research : an official journal of the American Association for Cancer Research Mar, 2011 | Pubmed ID: 21177410
Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments.
Cancer research Aug, 2011 | Pubmed ID: 21697283
Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.
Current pharmaceutical biotechnology Jul, 2012 | Pubmed ID: 21740359
Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2011 | Pubmed ID: 21844505
Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.
Molecular therapy : the journal of the American Society of Gene Therapy Feb, 2012 | Pubmed ID: 22031239
Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.
Cancer research Mar, 2012 | Pubmed ID: 22282654
Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells.
Advances in virology , 2012 | Pubmed ID: 22312364
The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFNγ generation.
Journal of virology Feb, 2012 | Pubmed ID: 22318143
MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.
Proceedings of the National Academy of Sciences of the United States of America Apr, 2012 | Pubmed ID: 22431589
Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.
Clinical cancer research : an official journal of the American Association for Cancer Research Sep, 2012 | Pubmed ID: 22753591
Extracellular vesicles and their convergence with viral pathways.
Advances in virology , 2012 | Pubmed ID: 22888349
Anti-angiogenic gene therapy in the treatment of malignant gliomas.
Neuroscience letters Oct, 2012 | Pubmed ID: 22906922
Bimodal anti-glioma mechanisms of cilengitide demonstrated by novel invasive glioma models.
Neuropathology : official journal of the Japanese Society of Neuropathology Apr, 2013 | Pubmed ID: 22989076
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Molecular therapy : the journal of the American Society of Gene Therapy Mar, 2013 | Pubmed ID: 23070115
NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
Nature medicine Dec, 2012 | Pubmed ID: 23178246
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
Molecular therapy : the journal of the American Society of Gene Therapy May, 2013 | Pubmed ID: 23481323
How can we trick the immune system into overcoming the detrimental effects of oncolytic viral therapy to treat glioblastoma?
Expert review of neurotherapeutics Apr, 2013 | Pubmed ID: 23545048
Gene expression profiling of the anti-glioma effect of Cilengitide.
SpringerPlus Dec, 2013 | Pubmed ID: 23667810
Cytomegalovirus contributes to glioblastoma in the context of tumor suppressor mutations.
Cancer research Jun, 2013 | Pubmed ID: 23729642
Systemic delivery of SapC-DOPS has antiangiogenic and antitumor effects against glioblastoma.
Molecular therapy : the journal of the American Society of Gene Therapy Aug, 2013 | Pubmed ID: 23732993
Brain-specific angiogenesis inhibitor-1 signaling, regulation, and enrichment in the postsynaptic density.
The Journal of biological chemistry Aug, 2013 | Pubmed ID: 23782696
STAT3 activation promotes oncolytic HSV1 replication in glioma cells.
PloS one , 2013 | Pubmed ID: 23936533
Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells.
PloS one , 2013 | Pubmed ID: 24039814
DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.
Clinical cancer research : an official journal of the American Association for Cancer Research Nov, 2013 | Pubmed ID: 24056786
Genetic Validation of the Protein Arginine Methyltransferase PRMT5 as a Candidate Therapeutic Target in Glioblastoma.
Cancer research Mar, 2014 | Pubmed ID: 24453002
Zhengtao Chu1,2,
Kathleen LaSance3,
Victor Blanco1,
Chang-Hyuk Kwon5,6,
Balveen Kaur5,6,
Malinda Frederick4,
Sherry Thornton4,
Lisa Lemen3,
Xiaoyang Qi1,2
1Division of Hematology-Oncology, Department of Internal Medicine, University of Cincinnati College of Medicine,
2Division of Human Genetics, University of Cincinnati College of Medicine,
3Department of Radiology, University of Cincinnati College of Medicine,
4Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine,
5Solid Tumor Biology Program, James Comprehensive Cancer Center, The Ohio State University Medical Center,
6Department of Neurological Surgery, James Comprehensive Cancer Center, The Ohio State University Medical Center
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved